Core Viewpoint - The announcement details a subscription agreement between IFGL, a direct non-wholly owned subsidiary of the company, and the subscriber, Sing Ming Life Science Group Limited, involving a total subscription price of HKD 177 million for 1.476 billion shares at an issue price of HKD 0.12 per share [1] Group 1 - IFGL's equity stake in the company will be diluted from 98.69% to approximately 79.21% following the completion of the subscription agreement [1] - IFGL will remain a subsidiary of the company, and its financial performance will continue to be consolidated into the group's financial statements [1] - The subscriber will hold approximately 19.74% of IFGL's shares post-completion, with the company becoming a major shareholder in the subscriber with an estimated 16.67% equity stake in the expanded issued share capital [1]
意力国际(00585)附属IFGL获信铭生命科技(00474)认购1.77亿港元认购股份